EQL Pharma ABOSTO:EQL -2.32%42 OCF Margin % is 13.97% as of Mar. 2026, which is 76% above its 10-year median of 7.92. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, EQL Pharma AB ranks worse than 57.96% on this metric.
The historical rank and industry rank for EQL Pharma AB's OCF Margin % or its related term are showing as below:
OSTO:EQL'
s OCF Margin % Range Over the Past 10 Years
Min: -6.6 Med: 7.92 Max: 33.52
Current: 6.56
During the past 13 years, the highest OCF Margin % of EQL Pharma AB was 33.52%. The lowest was -6.60%. And the median was 7.92%.
OSTO:EQL's OCF Margin % is ranked worse than 57.96% of 961
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs OSTO:EQL: 6.56
EQL Pharma AB OCF Margin % Related Terms
EQL Pharma AB OCF Margin % Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's OCF Margin % distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a OCF Margin % of 13.97% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on EQL Pharma AB and its competitors. This is 76% above median its historical median of 7.92. According to the industry distribution chart, EQL Pharma AB ranks #557 out of 961 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is EQL Pharma AB's OCF Margin % too high?
EQL Pharma AB's current OCF Margin % of 13.97% is 76% above median its 10-year median of 7.92. The Drug Manufacturers industry median OCF Margin % is 9.94. EQL Pharma AB's value of 13.97% is 40.5% above this industry median. Based on the distribution chart, EQL Pharma AB ranks #557 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #557 out of 961 companies for OCF Margin %. This places EQL Pharma AB in the lower half of its industry. The industry median OCF Margin % is 9.94. EQL Pharma AB's value of 13.97% is 40.5% above this benchmark. While the company's 10-year median is 7.92 vs. the industry median of 9.94, EQL Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current OCF Margin % of 13.97% is 40.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current OCF Margin % is 13.97%, which is 76% above median its own 10-year median of 7.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current OCF Margin % of 13.97%. The current OCF Margin % is 13.97%, which is 76% above median its 10-year median of 7.92 and 40.5% above the Drug Manufacturers industry median of 9.94. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current OCF Margin % is 13.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
